• Nurix Therapeutics will present updated Phase 1a/1b bexobrutideg (NX-5948) results at the American Society of Hematology meeting on December 13, 2026.
• Abstract results showed sustained clinical activity with favorable tolerability in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
• Efficacy findings covered patients previously treated with covalent BTK inhibitors; additional analyses will assess previously untreated patients and those with high-risk molecular features.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870591) on November 05, 2026, and is solely responsible for the information contained therein.